Setting

Asia Pacific Oral Antibiotics Market 2020-2030 by Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Application, Drug Type, and Country: Trend Forecast and Growth Opportunity

Published: 26 Aug 2020 | Report Code: 10247656 | Pages: 126

Asia Pacific oral antibiotics market will grow by 4.6% annually with a total addressable market cap of $103.3 billion over 2020-2030 owing to the rising infection complications associated with COVID-19 epidemic, development of innovative antibiotics, and growing healthcare expenditure. Highlighted with 35 tables and 62 figures, this 126-page report “Asia Pacific Oral Antibiotics Market 2020-2030 by Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Application, Drug Type, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific oral antibiotics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific oral antibiotics market in every aspect of the classification from perspectives of Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Application, Drug Type, and Country. Based on Drug Class, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. Cephalosporin • Cefuroxime Axetil • Cephalexin • Cefixime • Cefpodoxime • Other Cephalosporin Penicillin Macrolides Tetracycline Quinolones Sulfonamides Aminoglycosides Other Drug Classes Based on Action Mechanism, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Cell Wall Synthesis Inhibitors • Mycolic Acid Inhibitors • RNA Synthesis Inhibitors • DNA Synthesis Inhibitors • Protein Synthesis Inhibitors • Other Mechanisms Based on Drug Origin, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Natural Antibiotics • Semi-synthetic Antibiotics • Synthetic Antibiotics Based on Activity Spectrum, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Broad-spectrum Antibiotics • Narrow-spectrum Antibiotics Based on Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. Urinary Tract Infections (UTIS) • Upper Respiratory Tract Infections (URTI) • Lower Respiratory Tract Infections (LRTIs) Dental Infections • Monotherapies • Combined Therapies Respiratory Tract Infections (RTIS) Other Applications Based on Drug Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Brand Antibiotics • Generic Antibiotics Geographically, the following national/local markets are fully investigated: • Japan • China • South Korea • Australia • India • Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka) For each country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Drug Class, Drug Origin, and Application over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Specifically, potential risks associated with investing in Asia Pacific oral antibiotics market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions. Key Players (this may not be a complete list and extra companies can be added upon request): Abbott Laboratories Astellas Pharma AstraZeneca Plc Bayer AG Bristol Myers Squibb Company Cipla Inc. Dr. Reddy’s Laboratories Ltd. Eli Lilly and Company F. Hoffmann-La Roche Ltd. Gilead Sciences, Inc. GlaxoSmithKline plc. Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals) Mayne Pharma Group Ltd. MELINTA THERAPEUTICS, INC. Merck KGaA Novartis AG Pfizer Inc. Sanofi Sun Pharmaceutical Industries Ltd. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Table Of Contents

1 Introduction	7
1.1 Industry Definition and Research Scope	7
1.1.1 Industry Definition	7
1.1.2 Research Scope	8
1.2 Research Methodology	11
1.2.1 Overview of Market Research Methodology	11
1.2.2 Market Assumption	12
1.2.3 Secondary Data	12
1.2.4 Primary Data	12
1.2.5 Data Filtration and Model Design	14
1.2.6 Market Size/Share Estimation	15
1.2.7 Research Limitations	16
1.3 Executive Summary	17
2 Market Overview and Dynamics	20
2.1 Market Size and Forecast	20
2.1.1 Impact of COVID-19 on the Market	21
2.2 Major Growth Drivers	23
2.3 Market Restraints and Challenges	27
2.4 Emerging Opportunities and Market Trends	30
2.5 Porter’s Fiver Forces Analysis	34
3 Segmentation of Asia Pacific Market by Drug Class	38
3.1 Market Overview by Drug Class	38
3.2 Cephalosporin	40
3.3 Penicillin	42
3.4 Macrolides	43
3.5 Tetracycline	44
3.6 Quinolones	45
3.7 Sulfonamides	46
3.8 Aminoglycosides	47
3.9 Other Drug Classes	48
4 Segmentation of Asia Pacific Market by Action Mechanism	49
4.1 Market Overview by Action Mechanism	49
4.2 Cell Wall Synthesis Inhibitors	51
4.3 Mycolic Acid Inhibitors	52
4.4 RNA Synthesis Inhibitors	53
4.5 DNA Synthesis Inhibitors	54
4.6 Protein Synthesis Inhibitors	55
4.7 Other Mechanisms	56
5 Segmentation of Asia Pacific Market by Drug Origin	57
5.1 Market Overview by Drug Origin	57
5.2 Natural Antibiotics	59
5.3 Semi-synthetic Antibiotics	60
5.4 Synthetic Antibiotics	61
6 Segmentation of Asia Pacific Market by Activity Spectrum	62
6.1 Market Overview by Activity Spectrum	62
6.2 Broad-spectrum Antibiotics	64
6.3 Narrow-spectrum Antibiotics	65
7 Segmentation of Asia Pacific Market by Application	66
7.1 Market Overview by Application	66
7.2 Urinary Tract Infections (UTIS)	68
7.3 Dental Infections	69
7.3.1 Monotherapies for Dental Infections	70
7.3.2 Combined Therapies for Dental Infections	71
7.4 Respiratory Tract Infections (RTIS)	72
7.4.1 Upper Respiratory Tract Infections (URTI)	73
7.4.2 Lower Respiratory Tract Infections (LRTIs)	74
7.5 Other Applications	75
8 Segmentation of Asia Pacific Market by Drug Type	76
8.1 Market Overview by Drug Type	76
8.2 Brand Antibiotics	78
8.3 Generic Antibiotics	79
9 Asia-Pacific Market 2019-2030 by Country	80
9.1 Overview of Asia-Pacific Market	80
9.2 Japan	83
9.3 China	86
9.4 Australia	88
9.5 India	90
9.6 South Korea	92
9.7 Rest of APAC Region	94
10 Competitive Landscape	96
10.1 Overview of Key Vendors	96
10.2 New Product Launch, Partnership, Investment, and M&A	99
10.3 Company Profiles	100
Abbott Laboratories	100
Astellas Pharma	102
AstraZeneca Plc	103
Bayer AG	104
Bristol Myers Squibb Company	105
Cipla Inc.	106
Dr. Reddy’s Laboratories Ltd.	107
Eli Lilly and Company	108
F. Hoffmann-La Roche Ltd.	109
Gilead Sciences, Inc.	110
GlaxoSmithKline plc.	111
Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals)	112
Mayne Pharma Group Ltd.	113
MELINTA THERAPEUTICS, INC.	114
Merck KGaA	115
Novartis AG	116
Pfizer Inc.	117
Sanofi	118
Sun Pharmaceutical Industries Ltd.	119
11 Investing in Asia Pacific Market: Risk Assessment and Management	120
11.1 Risk Evaluation of Asia Pacific Market	120
11.2 Critical Success Factors (CSFs)	123
Related Reports and Products	126
List Of Tables

Table 1.  Snapshot of Asia Pacific Oral Antibiotics Market, 2019-2030	18
Table 2.  Main Product Trends and Market Opportunities in Asia Pacific Oral Antibiotics Market	30
Table 3. Asia Pacific Oral Antibiotics Market by Drug Class, 2019-2030, $ mn	38
Table 4. Asia Pacific Oral Antibiotics Market: Cephalosporin by Molecule, 2019-2030, $ mn	41
Table 5. Asia Pacific Oral Antibiotics Market by Action Mechanism, 2019-2030, $ mn	49
Table 6. Asia Pacific Oral Antibiotics Market by Drug Origin, 2019-2030, $ mn	57
Table 7. Asia Pacific Oral Antibiotics Market by Activity Spectrum, 2019-2030, $ mn	62
Table 8. Asia Pacific Oral Antibiotics Market by Application, 2019-2030, $ mn	66
Table 9. Asia Pacific Oral Antibiotics Market: Dental Infections by Type, 2019-2030, $ mn	69
Table 10. Asia Pacific Oral Antibiotics Market: Respiratory Tract Infections (RTIS) by Type, 2019-2030, $ mn	72
Table 11. Asia Pacific Oral Antibiotics Market by Drug Type, 2019-2030, $ bn	76
Table 12. APAC Oral Antibiotics Market by Country, 2019-2030, $ bn	81
Table 13. Japan Oral Antibiotics Market by Drug Class, 2019-2030, $ mn	85
Table 14. Japan Oral Antibiotics Market by Drug Origin, 2019-2030, $ mn	85
Table 15. Japan Oral Antibiotics Market by Application, 2019-2030, $ mn	85
Table 16. China Oral Antibiotics Market by Drug Class, 2019-2030, $ mn	87
Table 17. China Oral Antibiotics Market by Drug Origin, 2019-2030, $ mn	87
Table 18. China Oral Antibiotics Market by Application, 2019-2030, $ mn	87
Table 19. Australia Oral Antibiotics Market by Drug Class, 2019-2030, $ mn	89
Table 20. Australia Oral Antibiotics Market by Drug Origin, 2019-2030, $ mn	89
Table 21. Australia Oral Antibiotics Market by Application, 2019-2030, $ mn	89
Table 22. India Oral Antibiotics Market by Drug Class, 2019-2030, $ mn	91
Table 23. India Oral Antibiotics Market by Drug Origin, 2019-2030, $ mn	91
Table 24. India Oral Antibiotics Market by Application, 2019-2030, $ mn	91
Table 25. South Korea Oral Antibiotics Market by Drug Class, 2019-2030, $ mn	93
Table 26. South Korea Oral Antibiotics Market by Drug Origin, 2019-2030, $ mn	93
Table 27. South Korea Oral Antibiotics Market by Application, 2019-2030, $ mn	93
Table 28. Oral Antibiotics Market in Rest of APAC by Country, 2019-2030, $ bn	95
Table 29. Abbott Laboratories: Company Snapshot	100
Table 30. Abbott Laboratories: Business Segmentation	100
Table 31. Abbott Laboratories: Product Portfolio	101
Table 32. Abbott Laboratories: Revenue, 2016-2018, $ mn	101
Table 33. Abbott Laboratories: Recent Developments	101
Table 34.  Risk Evaluation for Investing in Asia Pacific Market, 2019-2030	121
Table 35. Critical Success Factors and Key Takeaways	124


List Of Figures

Figure 1. Research Method Flow Chart	11
Figure 2. Breakdown of Primary Research	13
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation	15
Figure 4. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030	17
Figure 5. Asia Pacific Oral Antibiotics Market, 2019-2030, $ mn	20
Figure 6. Impact of COVID-19 on Business	21
Figure 7. Primary Drivers and Impact Factors of Asia Pacific Oral Antibiotics Market	23
Figure 8. GDP per capita in the World, 1960-2018, $ thousand	26
Figure 9. Forecast of Middle-class Population by Region, 2015-2030, million	26
Figure 10. Primary Restraints and Impact Factors of Asia Pacific Oral Antibiotics Market	27
Figure 11. Investment Opportunity Analysis	31
Figure 12. Porter’s Fiver Forces Analysis of Asia Pacific Oral Antibiotics Market	34
Figure 13. Breakdown of Asia Pacific Oral Antibiotics Market by Drug Class, 2019-2030, % of Revenue	39
Figure 14. Asia Pacific Addressable Market Cap in 2020-2030 by Drug Class, Value ($ mn) and Share (%)	39
Figure 15. Asia Pacific Oral Antibiotics Market: Cephalosporin, 2019-2030, $ mn	40
Figure 16. Asia Pacific Oral Antibiotics Market: Penicillin, 2019-2030, $ mn	42
Figure 17. Asia Pacific Oral Antibiotics Market: Macrolides, 2019-2030, $ mn	43
Figure 18. Asia Pacific Oral Antibiotics Market: Tetracycline, 2019-2030, $ mn	44
Figure 19. Asia Pacific Oral Antibiotics Market: Quinolones, 2019-2030, $ mn	45
Figure 20. Asia Pacific Oral Antibiotics Market: Sulfonamides, 2019-2030, $ mn	46
Figure 21. Asia Pacific Oral Antibiotics Market: Aminoglycosides, 2019-2030, $ mn	47
Figure 22. Asia Pacific Oral Antibiotics Market: Other Drug Classes, 2019-2030, $ mn	48
Figure 23. Breakdown of Asia Pacific Oral Antibiotics Market by Action Mechanism, 2019-2030, % of Sales Revenue	50
Figure 24. Asia Pacific Addressable Market Cap in 2020-2030 by Action Mechanism, Value ($ mn) and Share (%)	50
Figure 25. Asia Pacific Oral Antibiotics Market: Cell Wall Synthesis Inhibitors, 2019-2030, $ mn	51
Figure 26. Asia Pacific Oral Antibiotics Market: Mycolic Acid Inhibitors, 2019-2030, $ mn	52
Figure 27. Asia Pacific Oral Antibiotics Market: RNA Synthesis Inhibitors, 2019-2030, $ mn	53
Figure 28. Asia Pacific Oral Antibiotics Market: DNA Synthesis Inhibitors, 2019-2030, $ mn	54
Figure 29. Asia Pacific Oral Antibiotics Market: Protein Synthesis Inhibitors, 2019-2030, $ mn	55
Figure 30. Asia Pacific Oral Antibiotics Market: Other Mechanisms, 2019-2030, $ mn	56
Figure 31. Breakdown of Asia Pacific Oral Antibiotics Market by Drug Origin, 2019-2030, % of Sales Revenue	58
Figure 32. Asia Pacific Addressable Market Cap in 2020-2030 by Drug Origin, Value ($ mn) and Share (%)	58
Figure 33. Asia Pacific Oral Antibiotics Market: Natural Antibiotics, 2019-2030, $ mn	59
Figure 34. Asia Pacific Oral Antibiotics Market: Semi-synthetic Antibiotics, 2019-2030, $ mn	60
Figure 35. Asia Pacific Oral Antibiotics Market: Synthetic Antibiotics, 2019-2030, $ mn	61
Figure 36. Breakdown of Asia Pacific Oral Antibiotics Market by Activity Spectrum, 2019-2030, % of Revenue	63
Figure 37. Asia Pacific Addressable Market Cap in 2020-2030 by Activity Spectrum, Value ($ mn) and Share (%)	63
Figure 38. Asia Pacific Oral Antibiotics Market: Broad-spectrum Antibiotics, 2019-2030, $ mn	64
Figure 39. Asia Pacific Oral Antibiotics Market: Narrow-spectrum Antibiotics, 2019-2030, $ mn	65
Figure 40. Breakdown of Asia Pacific Oral Antibiotics Market by Application, 2019-2030, % of Revenue	67
Figure 41. Asia Pacific Addressable Market Cap in 2020-2030 by Application, Value ($ mn) and Share (%)	67
Figure 42. Asia Pacific Oral Antibiotics Market: Urinary Tract Infections (UTIS), 2019-2030, $ mn	68
Figure 43. Asia Pacific Oral Antibiotics Market: Dental Infections, 2019-2030, $ mn	69
Figure 44. Asia Pacific Oral Antibiotics Market: Monotherapies for Dental Infections, 2019-2030, $ mn	70
Figure 45. Asia Pacific Oral Antibiotics Market: Combined Therapies for Dental Infections, 2019-2030, $ mn	71
Figure 46. Asia Pacific Oral Antibiotics Market: Respiratory Tract Infections (RTIS), 2019-2030, $ mn	72
Figure 47. Asia Pacific Oral Antibiotics Market: Upper Respiratory Tract Infections (URTI), 2019-2030, $ mn	73
Figure 48. Asia Pacific Oral Antibiotics Market: Lower Respiratory Tract Infections (LRTIs), 2019-2030, $ mn	74
Figure 49. Asia Pacific Oral Antibiotics Market: Other Applications, 2019-2030, $ mn	75
Figure 50. Breakdown of Asia Pacific Oral Antibiotics Market by Drug Type, 2019-2030, % of Revenue	76
Figure 51. Asia Pacific Addressable Market Cap in 2020-2030 by Drug Type, Value ($ bn) and Share (%)	77
Figure 52. Asia Pacific Oral Antibiotics Market: Brand Antibiotics, 2019-2030, $ bn	78
Figure 53. Asia Pacific Oral Antibiotics Market: Generic Antibiotics, 2019-2030, $ bn	79
Figure 54. Breakdown of APAC Oral Antibiotics Market by Country, 2019 and 2030, % of Revenue	81
Figure 55. Contribution to APAC 2020-2030 Cumulative Revenue by Country, Value ($ bn) and Share (%)	82
Figure 56.  Oral Antibiotics Market in Japan, 2019-2030, $ bn	84
Figure 57.  Oral Antibiotics Market in China, 2019-2030, $ bn	86
Figure 58.  Oral Antibiotics Market in Australia, 2019-2030, $ bn	88
Figure 59.  Oral Antibiotics Market in India, 2019-2030, $ bn	90
Figure 60.  Oral Antibiotics Market in South Korea, 2019-2030, $ bn	92
Figure 61.  Oral Antibiotics Market in Rest of APAC, 2019-2030, $ bn	94
Figure 62. Growth Stage of Asia Pacific Oral Antibiotics Industry over the Forecast Period	96

Key Players (this may not be a complete list and extra companies can be added upon request): 
Abbott Laboratories	
Astellas Pharma	
AstraZeneca Plc	
Bayer AG	
Bristol Myers Squibb Company	
Cipla Inc.	
Dr. Reddy’s Laboratories Ltd.	
Eli Lilly and Company	
F. Hoffmann-La Roche Ltd.	
Gilead Sciences, Inc.	
GlaxoSmithKline plc.	
Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals)	
Mayne Pharma Group Ltd.	
MELINTA THERAPEUTICS, INC.	
Merck KGaA	
Novartis AG	
Pfizer Inc.	
Sanofi	
Sun Pharmaceutical Industries Ltd.